118 related articles for article (PubMed ID: 34965093)
1.
Xiao X; Sarma S; Menegatti S; Crook N; Magness ST; Hall CK
ACS Chem Biol; 2022 Jan; 17(1):118-128. PubMed ID: 34965093
[No Abstract] [Full Text] [Related]
2. Design of 8-mer Peptides that Block
Sarma S; Catella CM; Pedro ETS; Xiao X; Durmusoglu D; Menegatti S; Crook N; Magness ST; Hall CK
bioRxiv; 2023 Jan; ():. PubMed ID: 36711911
[TBL] [Abstract][Full Text] [Related]
3. Epitopes and Mechanism of Action of the Clostridium difficile Toxin A-Neutralizing Antibody Actoxumab.
Hernandez LD; Kroh HK; Hsieh E; Yang X; Beaumont M; Sheth PR; DiNunzio E; Rutherford SA; Ohi MD; Ermakov G; Xiao L; Secore S; Karczewski J; Racine F; Mayhood T; Fischer P; Sher X; Gupta P; Lacy DB; Therien AG
J Mol Biol; 2017 Apr; 429(7):1030-1044. PubMed ID: 28232034
[TBL] [Abstract][Full Text] [Related]
4. Use of a neutralizing antibody helps identify structural features critical for binding of
Kroh HK; Chandrasekaran R; Rosenthal K; Woods R; Jin X; Ohi MD; Nyborg AC; Rainey GJ; Warrener P; Spiller BW; Lacy DB
J Biol Chem; 2017 Sep; 292(35):14401-14412. PubMed ID: 28705932
[No Abstract] [Full Text] [Related]
5. Functional properties of the carboxy-terminal host cell-binding domains of the two toxins, TcdA and TcdB, expressed by Clostridium difficile.
Dingle T; Wee S; Mulvey GL; Greco A; Kitova EN; Sun J; Lin S; Klassen JS; Palcic MM; Ng KK; Armstrong GD
Glycobiology; 2008 Sep; 18(9):698-706. PubMed ID: 18509107
[TBL] [Abstract][Full Text] [Related]
6. A mixture of functionally oligoclonal humanized monoclonal antibodies that neutralize Clostridium difficile TcdA and TcdB with high levels of in vitro potency shows in vivo protection in a hamster infection model.
Davies NL; Compson JE; Mackenzie B; O'Dowd VL; Oxbrow AK; Heads JT; Turner A; Sarkar K; Dugdale SL; Jairaj M; Christodoulou L; Knight DE; Cross AS; Hervé KJ; Tyson KL; Hailu H; Doyle CB; Ellis M; Kriek M; Cox M; Page MJ; Moore AR; Lightwood DJ; Humphreys DP
Clin Vaccine Immunol; 2013 Mar; 20(3):377-90. PubMed ID: 23324518
[TBL] [Abstract][Full Text] [Related]
7. Development and characterization of phage display-derived anti-toxin antibodies neutralizing TcdA and TcdB of
Raeisi H; Azimirad M; Asadzadeh Aghdaei H; Zarnani AH; Abdolalizadeh J; Yadegar A; Zali MR
Microbiol Spectr; 2023 Sep; 11(5):e0531022. PubMed ID: 37668373
[TBL] [Abstract][Full Text] [Related]
8. Inhibition of Clostridium difficile TcdA and TcdB toxins with transition state analogues.
Paparella AS; Aboulache BL; Harijan RK; Potts KS; Tyler PC; Schramm VL
Nat Commun; 2021 Nov; 12(1):6285. PubMed ID: 34725358
[TBL] [Abstract][Full Text] [Related]
9. Biochemical and Immunological Characterization of Truncated Fragments of the Receptor-Binding Domains of C. difficile Toxin A.
Huang JH; Shen ZQ; Lien SP; Hsiao KN; Leng CH; Chen CC; Siu LK; Chong PC
PLoS One; 2015; 10(8):e0135045. PubMed ID: 26271033
[TBL] [Abstract][Full Text] [Related]
10. The structure of Clostridium difficile toxin A glucosyltransferase domain bound to Mn2+ and UDP provides insights into glucosyltransferase activity and product release.
D'Urzo N; Malito E; Biancucci M; Bottomley MJ; Maione D; Scarselli M; Martinelli M
FEBS J; 2012 Sep; 279(17):3085-97. PubMed ID: 22747490
[TBL] [Abstract][Full Text] [Related]
11. Structural basis for antibody recognition in the receptor-binding domains of toxins A and B from Clostridium difficile.
Murase T; Eugenio L; Schorr M; Hussack G; Tanha J; Kitova EN; Klassen JS; Ng KK
J Biol Chem; 2014 Jan; 289(4):2331-43. PubMed ID: 24311789
[TBL] [Abstract][Full Text] [Related]
12. High temporal resolution of glucosyltransferase dependent and independent effects of Clostridium difficile toxins across multiple cell types.
D'Auria KM; Bloom MJ; Reyes Y; Gray MC; van Opstal EJ; Papin JA; Hewlett EL
BMC Microbiol; 2015 Feb; 15(1):7. PubMed ID: 25648517
[TBL] [Abstract][Full Text] [Related]
13. Masking autoprocessing of Clostridium difficile toxin A by the C-terminus combined repetitive oligo peptides.
Zhang Y; Hamza T; Gao S; Feng H
Biochem Biophys Res Commun; 2015 Apr; 459(2):259-263. PubMed ID: 25725153
[TBL] [Abstract][Full Text] [Related]
14. The enterotoxicity of Clostridium difficile toxins.
Sun X; Savidge T; Feng H
Toxins (Basel); 2010 Jul; 2(7):1848-80. PubMed ID: 22069662
[TBL] [Abstract][Full Text] [Related]
15. The Role of Rho GTPases in Toxicity of Clostridium difficile Toxins.
Chen S; Sun C; Wang H; Wang J
Toxins (Basel); 2015 Dec; 7(12):5254-67. PubMed ID: 26633511
[TBL] [Abstract][Full Text] [Related]
16. Effective Sequestration of Clostridium difficile Protein Toxins by Calcium Aluminosilicate.
Sturino JM; Pokusaeva K; Carpenter R
Antimicrob Agents Chemother; 2015 Dec; 59(12):7178-83. PubMed ID: 26149988
[TBL] [Abstract][Full Text] [Related]
17. Development of a non-radiolabeled glucosyltransferase activity assay for C. difficile toxin A and B using ultra performance liquid chromatography.
Loughney JW; Lancaster C; Price CE; Hoang VM; Ha S; Rustandi RR
J Chromatogr A; 2017 May; 1498():169-175. PubMed ID: 28238427
[TBL] [Abstract][Full Text] [Related]
18. Cysteine Protease-Mediated Autocleavage of
Zhang Y; Li S; Yang Z; Shi L; Yu H; Salerno-Goncalves R; Saint Fleur A; Feng H
Cell Mol Gastroenterol Hepatol; 2018; 5(4):611-625. PubMed ID: 29930981
[TBL] [Abstract][Full Text] [Related]
19. A DNA vaccine targeting TcdA and TcdB induces protective immunity against Clostridium difficile.
Zhang BZ; Cai J; Yu B; Hua Y; Lau CC; Kao RY; Sze KH; Yuen KY; Huang JD
BMC Infect Dis; 2016 Oct; 16(1):596. PubMed ID: 27770789
[TBL] [Abstract][Full Text] [Related]
20. Intrinsic Toxin-Derived Peptides Destabilize and Inactivate
Larabee JL; Bland SJ; Hunt JJ; Ballard JD
mBio; 2017 May; 8(3):. PubMed ID: 28512094
[No Abstract] [Full Text] [Related]
[Next] [New Search]
